Navigation Links
Cadence Pharmaceuticals Reports First Quarter 2013 Financial Results
Date:5/2/2013

Pharmaceuticals, Inc.

WCGPhone: 858-436-1400

Phone: 415-946-1076   CADENCE PHARMACEUTICALS, INC.CONDENSED STATEMENTS OF OPERATIONS(unaudited)(in thousands, except per share amounts)Three Months EndedMarch 31,20132012Revenue:Product revenue, net

$
23,612$
8,004Total revenues

23,6128,004Costs and expenses:Cost of product sales

8,1674,246Amortization of patent license

336336Research and development

1,3631,511Selling, general and administrative

21,63523,531Other

50-Total costs and expenses

31,55129,624Loss from operations

(7,939)(21,620)Other income (expense), net

6,576(1,053)Net loss

$
(1,363)$
(22,673)Basic and diluted net loss per share

$
(0.02)$
(0.27)Shares used to compute basic anddiluted net loss per share

85,67285,519 CADENCE PHARMACEUTICALS, INC.CONDENSED BALANCE SHEETS(in thousands)March 31,December 31,20132012(unaudited)AssetsCurrent assets:Cash, cash equivalents and short-term investments 

$
4,240$
2,072Restricted cash 

640640Accounts receivable, net 

8,9086,152Inventory 

6,0836,498Prepaid expenses and other current assets 

2,0411,154Total current assets

81,91276,516Property and equipment, net

1,9051,967Intangible assets, net

11,75412,090Other assets

907,106Total assets

$
95,661$
97,679Liabilities and Stockholders' Equity Current liabilities:Accounts payable 

$
5,808$
5,796Accrued liabilities 

12,53212,969Deferred revenue 

-2,234Current debt, less discount 

2,552-Total current liabilities

20,89220,999Other liabilities

23351Long-term debt, less discount

26,38828,818Total stockholders' equity

48,14847,811Total liabilities and stockholders' equity

$
95,661
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Cadence Pharmaceuticals Reports Second Quarter 2012 Financial Results
2. Cadence Pharmaceuticals To Present At The Deutsche Bank Securities, Inc. 37th Annual Health Care Conference In Boston On May 8, 2012
3. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2011 Financial Results on March 12, 2012
4. Valeant Pharmaceuticals Announces Extension of the Expiration Date for Its Previously Announced Tender Offer for All Outstanding Shares of Common Stock of Obagi Medical Products, Inc.
5. VentiRx Pharmaceuticals Appoints James Kyle Bryan, M.D. as Chief Medical Officer
6. Aurigenes Collaboration Programs with Endo Pharmaceuticals Reach Important Milestones
7. Vanda Pharmaceuticals Appoints Dr. Paolo Baroldi As Chief Medical Officer
8. Next Silicon Valley BioTalks Tackles “Is EDC Becoming a Commodity?” at Onyx Pharmaceuticals HQ
9. Global Nuclear Medicine / Radiopharmaceuticals Market worth $5.55 Billion by 2017
10. US Radiopharmaceuticals (USR) Awards Contract to Von Gahlen International for New Technetium-99m Generator Production Line Using Low Enriched Uranium Molybdenum-99
11. Anthera Pharmaceuticals Reports 2012 Fourth Quarter And Fiscal Year Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... 21, 2015 As part of its ... (BDWMC), Sun Health Foundation funded a $3.25 million project ... pharmacy with the most up-to-date features and technology. , ... The pharmacy's 45 staff members will begin moving from ... in the coming days. , The current pharmacy ...
(Date:5/20/2015)... SAN FRANCISCO, Calif. , May 20, 2015 ... VCYT ) today presented preliminary data demonstrating the ... distinguish idiopathic pulmonary fibrosis (IPF) from other interstitial ... The findings suggest the classifier,s potential to help ... surgery to resolve ambiguity in IPF diagnosis – ...
(Date:5/20/2015)... (PRWEB) May 20, 2015 The global ... of 22.3% during the forecast period of 2015 to ... increasingly being used in drug discovery and development process ... market growth. In addition to this,heavy investments by key ... applications are also propelling market growth. Browse 113 market ...
(Date:5/20/2015)... 20, 2015  Cypher Genomics, Inc., a leading ... Celgene Corporation to apply Cypher,s Coral TM ... with patient response to innovative medicines. The information ... accelerate patient access to the right medicine at ... and development and potentially inform new companion diagnostics.  ...
Breaking Biology Technology:Sun Health Foundation Provides $3.25M to Expand, Relocate Banner Del E. Webb Medical Center Pharmacy 2Sun Health Foundation Provides $3.25M to Expand, Relocate Banner Del E. Webb Medical Center Pharmacy 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 2Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 4Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 5Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 2Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 3Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 4Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 5Cypher Genomics Collaborates with Celgene Corporation to Identify Novel Genomic Biomarkers 2
... called Clostridium has a protective coat of armour that ... on its own, which may have important commercial uses ... September 2007) at the Society for General Microbiology,s 161st ... from 3-6 September 2007. , Like many other micro-organisms, ...
... 99% Year-Over-Year, SHANGHAI, China, Sept. 5 ... WX ) ("WuXi PharmaTech" or "the Company"), ... development,outsourcing company, today announced its unaudited financial ... 2007. (Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO ), ...
... Alba Therapeutics Corporation today,announced that its Investigational New ... endogenous insulin production capacity in new-onset,type 1 diabetes ... period,by the U.S. Food and Drug Administration (FDA). ... in 2008 while focusing the majority,of its development ...
Cached Biology Technology:WuXi PharmaTech Announces Second Quarter 2007 Results 2WuXi PharmaTech Announces Second Quarter 2007 Results 3WuXi PharmaTech Announces Second Quarter 2007 Results 4WuXi PharmaTech Announces Second Quarter 2007 Results 5WuXi PharmaTech Announces Second Quarter 2007 Results 6WuXi PharmaTech Announces Second Quarter 2007 Results 7WuXi PharmaTech Announces Second Quarter 2007 Results 8WuXi PharmaTech Announces Second Quarter 2007 Results 9WuXi PharmaTech Announces Second Quarter 2007 Results 10Alba Therapeutics Announces IND for Beta Cell Preservation in Type 1 Diabetes Using AT-1001 2
(Date:4/27/2015)... , April 27, 2015  For more than ... trade show has been the premier worldwide event for ... 2015 is a must-attend event for any local, national, ... into the emerging commercial markets and current applications of ... innovations of this projected $48 billion industry, and how ...
(Date:4/20/2015)... , April 20, 2015 The ... Glenbeigh Records Management (GRM), Ireland,s ... Dubai Islamic Bank. Having built up an impressive track record ... a leading player within the records management sector in ... to double is GCC staffbase and employ a further eight ...
(Date:4/13/2015)... 2015  higi, a leading cloud-based consumer engagement platform ... engage with their communities around health and wellness, announced ... secure API.  ... affordable, and convenient vehicle to receive validated health information ... The API will allow higi,s trusted partners, on ...
Breaking Biology News(10 mins):UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 2UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 3UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 4UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 5Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3
... rare species of forget-me-nots have been added to Flora ... mountains of the South Island during an expedition led by Dr. ... an article published in the open access journal PhytoKeys ... group of botanists at the Museum of New Zealand ...
... pioneering surgical blood salvage technology developed at the University ... major surgery is carried out by reducing blood loss ... health care sector after gaining the CE mark and ... in the world leading University of Kirikkale University Hospital ...
... international team led by New York University School of ... world, has completed the first genome-wide and single-nucleotide resolution ... and Harpegnathos saltator . It provides new ... differentiation of ants and also shed light on the ...
Cached Biology News:No ordinary forget-me-nots 2New technology to transform blood processing 2New technology to transform blood processing 3The first ant methylomes uncover the relationship between DNA methylation and caste differentiation 2The first ant methylomes uncover the relationship between DNA methylation and caste differentiation 3
Carrier-Free Recombinant Human Flt-3/Flk-2 Ligand (Flt3/Flk2 Ligand, Flt3L, Flt3-L, Flk2L, Flk2-L) 100 ug...
... Mouse pan B (B220), 4.5 m, ... the efficient positive isolation or depletion ... spleen or lymph node cell suspensions. ... B cells and lytically active subsets ...
... agent and DNA-topoisomersae II inhibitor (IC50 = 59.2 ... C 29 H 32 O 13 ... Store at: RT ... Soluble to 100 mM ...
POU domain, class 2, transcription factor 2,...
Biology Products: